$99.41
3.67% day before yesterday
Nasdaq, Nov 14, 10:00 pm CET
ISIN
US76243J1051
Symbol
RYTM

Rhythm Pharmaceuticals, Inc. Stock price

$99.41
-5.79 5.50% 1M
+42.13 73.55% 6M
+43.43 77.58% YTD
+39.64 66.32% 1Y
+73.68 286.36% 3Y
+77.52 354.13% 5Y
+69.41 231.37% 10Y
+69.41 231.37% 20Y
Nasdaq, Closing price Fri, Nov 14 2025
+3.52 3.67%
ISIN
US76243J1051
Symbol
RYTM
Industry

Key metrics

Basic
Market capitalization
$6.6b
Enterprise Value
$6.3b
Net debt
positive
Cash
$416.1m
Shares outstanding
66.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
38.1 | 34.9
EV/Sales
36.3 | 33.3
EV/FCF
negative
P/B
22.4
Financial Health
Equity Ratio
42.0%
Return on Equity
-160.8%
ROCE
-46.3%
ROIC
-412.7%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$174.3m | $190.1m
EBITDA
$-184.8m | $-179.0m
EBIT
$-186.2m | $-184.8m
Net Income
$-197.7m | $-204.4m
Free Cash Flow
$-109.1m
Growth (TTM | estimate)
Revenue
25.9% | 46.1%
EBITDA
54.2% | 32.2%
EBIT
54.1% | 30.4%
Net Income
50.9% | 22.7%
Free Cash Flow
12.3%
Margin (TTM | estimate)
Gross
89.4%
EBITDA
-106.0% | -94.2%
EBIT
-106.8%
Net
-113.4% | -107.5%
Free Cash Flow
-62.6%
More
EPS
$-3.0
FCF per Share
$-1.6
Short interest
10.0%
Employees
283
Rev per Employee
$460.0k
Show more

Is Rhythm Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Rhythm Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

19x Buy
95%
1x Hold
5%

Analyst Opinions

20 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

Buy
95%
Hold
5%

Financial data from Rhythm Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
174 174
26% 26%
100%
- Direct Costs 18 18
18% 18%
11%
156 156
27% 27%
89%
- Selling and Administrative Expenses 176 176
2% 2%
101%
- Research and Development Expense 166 166
53% 53%
95%
-185 -185
54% 54%
-106%
- Depreciation and Amortization 1.45 1.45
9% 9%
1%
EBIT (Operating Income) EBIT -186 -186
54% 54%
-107%
Net Profit -198 -198
51% 51%
-113%

In millions USD.

Don't miss a Thing! We will send you all news about Rhythm Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rhythm Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
6 days ago
– Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant treatment with GLP-1 therapy – – Analysis of data from Phase 3 TRANSCEND trial show clinically meaningful changes in cardiometabolic parameters in patients with acquired hypothalamic obesity treated with setmelanotide for 52 weeks – BOSTON, Nov. 1...
Negative
The Motley Fool
8 days ago
Rythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, recently exercised and sold some stock options. Shulman still held 8,509 shares directly after the trade.
Neutral
GlobeNewsWire
9 days ago
-- FDA sets updated PDUFA goal date of March 20, 2026 –  -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (F...
More Rhythm Pharmaceuticals, Inc. News

Company Profile

Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Head office United States
CEO David Meeker
Employees 283
Founded 2008
Website rhythmtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today